Alkermes plc (ALKS)
Symbol Info
Listed Symbol ALKS
Name Alkermes plc
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $1,094,274,000
Latest Fiscal EPS $-0.89
Price Info
21 Day Moving Average $19.7710
21 Day EMA $19.300010
50 Day Moving Average $20.6542
50 Day EMA $20.536170
200 Day EMA $26.697400
200 Day Moving Average 26.955800
52 Week High $43.22
52 Week Low $17.11
52 Week Change $-56.672300
Alpha -0.019004
Beta 1.7771
Standard Deviation 0.129695
R2 0.221640
Periods 60
Share Information
10 Day Average Volume 1,080,341
20 Day Average Volume 1,198,338
30 Day Average Volume 1,127,008
50 Day Average Volume 1,103,595
Outstanding Shares 157,130,612
Float Shares 155,151,096
Percent Float 98.74%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 618
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 14,580,008
Institute Holdings Percent -
Institute Sold Previous 3 Months 24,201,708
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 2
Insider Holdings Percent 1.30%
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,979,516
Price Change
7 Day Price Change $-0.4699993
7 Day Percent Change -2.54%
21 Day Price Change $-3.1800003
21 Day Percent Change -15.00%
30 Day Price Change $-5.1099987
30 Day Percent Change -22.09%
Month To Date Price Change $-1.49
Month To Date Percent -7.64%
90 Day Price Change $-4.92
90 Day Percent Change -21.45%
Quarter To Date $-1.49
Quarter To Date Percent -7.64%
180 Day Price Change $-17.89
180 Day Percent Change -49.82%
200 Day Price Change $-15.360001
200 Day Percent Change -46.02%
Year To Date $-11.49
Year To Date Percent -38.94%
Profile
Description Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.
Details
Issue Type CS
Market Cap $2,831,493,628
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 157,130,612
CEO Richard F. Pops
Employees 2,300
Last Audit UE
Classification
CIK 0001520262
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 1 Burlington Road
Connaught House
Dublin, 4
Website http://www.alkermes.com
Facisimile
Telephone +353 17728000
Email
Key Ratios
Profitability
EBIT Margin -15.2
EBITDA Margin -6.6
Pre-Tax Profit Margin -18.8
Profit Margin Cont -18.09
Gross Margin 44.00
Profit Margin TOT -18.09
Income Statements
Revenue $818,736,000
Revenue Per Share $5.2105
Revenue 3 Years $9.54
Revenue 5 Years $10.95
Valuation Measures
PE Ratio -
Enterprise Value $2,791,122,240
Price To Sales 3.458372
Price To Free Cash 1,211.600000
PE High Last 5 Years -
Price To Book 2.7
Price To Cash Flow 31.2
PE Low Last 5 Years -
Price To Tangible Book 3.5
Financial Strength
Total Debt To Equity 0.3
Int Coverage -11.7
Current Ratio 3.0
Leverage Ratio 1.6
Quick Ratio 2.5
Long Term Debt To Capital 0.21
Assets
Receivables Turnover 1.3
Invoice Turnover 6.10
Assets Turnover 0.20
Management Effectiveness
Return Assets -10.42
Return On Equity -16.23
Return On Capital -12.87
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ALKS
Alkermes
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.